Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Agrippal

Novartis building

Novartis gets speedy FDA review for midostaurin

Leukaemia treatment could become first targeted therapy for 25 years

National Institute for Health and Care Excellence NICE logo

NICE backs Novartis’ Afinitor and Pfizer’s Xalkori

Provisionally approves breast and lung cancer drugs after greater discounts offered

- PMLiVE

MHRA launches medicines side effects awareness drive

Creates social media campaign as part of EU-wide initiative

Celgene building

Celgene engages IBM Watson for patient safety work

Aims to improve its pharmacovigilance methods with a new cloud-based platform

Immunisation politicised

The case of Human Papilloma Virus

- PMLiVE

GSK’s Bexsero vaccine growing fast, despite “tight” supply

Meningitis drug’s sales double as third quarter results exceed expectations

Novartis Gehry Building

Novartis says its biosimilar sales should reach $1bn this year

Four-drug portfolio grew by 40% to $262m in the quarter

- PMLiVE

Opening up innovation

Paul-Peter Tak on GlaxoSmithKline’s R&D strategy and the pivotal role of immunology

- PMLiVE

GSK’s blockbuster hopeful Shingrix filed in US

Clinical data showed shingles vaccine had 90% efficacy in elderly patients

- PMLiVE

After delay, Merck gets US approval for serious infection drug

Zinplava anticipated to accrue $300m in sales by 2020

- PMLiVE

PMEA 2016 finalists announced

AbbVie, Bayer, Celgene and Novartis are up for the prestigious Company of the Year

Roche Basel Switzerland

Roche snags pair of FDA breakthrough designations

Accelerates approval process for NSCLC treatment Alecensa and immunotherapy Actemra

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links